Review Article Open Access
Micro RNA Regulation of Cancer Stem Cell Phenotypes
Jennifer Lynch1 and Jenny Y Wang1,2*
1Cancer and Stem Cell Biology Group, Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2052, Australia
2School of Women’s and Children’s Health, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia
*Corresponding author: Jenny Y Wang, Cancer and Stem Cell Biology Group, Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2052, Australia, Tel: +61-(2)-9385-1554; E-mail:
Received: December 19, 2013; Accepted: January 07, 2014; Published: January 09, 2014
Citation: Lynch J, Wang JY (2014) Micro RNA Regulation of Cancer Stem Cell Phenotypes SOJ Genet Sci 1(1), 1-8. DOI: 10.15226/2377-4274/1/1/00101
Abstract Top
A small subpopulation of cancer cells, termed cancer stem cells (CSCs), are primarily responsible for initiating metastasis, resistance to therapy and ultimately patient relapse. If any improvements in long-term patient survival are to be achieved it is vital to target this highly tumorigenic population of cells. The cancer stem-like phenotype is defined by the capability to self-renew, differentiate and proliferate. A number of signaling pathways and stem cell markers have been demonstrated to regulate these vital activities, including Wnt/β-catenin, Hedgehog, Notch, BMI-1 and HMGA2. Intense interest is now focused on developing strategies to eliminate the CSC population. In this regard, several microRNAs (miRNAs), including miR-451, miR-34a, miR-17-92 and miR-200, have been demonstrated to regulate these fundamental CSC signaling pathways and consequently modulate the cancer stem cell phenotype. Thus, modulation of CSC-related miRNAs may represent a plausible mechanism for targeting the CSC population. The pleiotropic nature of miRNA activity can be exploited in a therapeutic manner to simultaneously inhibit multiple key regulators of the CSC phenotype and potentially achieve more efficacious targeting. This article will review our current understanding of the role of miRNAs in regulating CSC signaling pathways. In particular, this review will provide a better understanding of the role of specific miRNAs in regulating the key CSC signaling pathways and highlight several miRNAs that could be therapeutically applicable to eliminate the CSC population.
Keywords: Leukemia stem cell; MicroRNA; Self-renewal
Metastatic dissemination of disease, the emergence of resistance to therapy and ultimately relapse of the disease state are the primary cause of treatment failure among cancer patients [1-3]. In recent years, it has become apparent that a subpopulation of tumor cells is primarily responsible for driving tumor progression and resistance to therapy in some cancers [4,5]. These cells, termed cancer stem cells (CSCs), possess the unique characteristics of self-renewal, ability to differentiate and high tumorigenic potential when injected into recipient mice [6]. The persistence of CSCs is believed to be the ultimate cause of treatment failure for current cancer therapy regimens [7,8]. Thus, it is imperative to develop mechanisms to specifically target and eradicate the cancer stem cell population.
MiRNAs have been receiving intense interest as promising targeted therapeutic agents. Their activity as endogenous regulators of gene expression, their stability in body fluids and the multi-target nature of their activity indicates that miRNA-mediated therapeutics could produce efficacious results with minimal antigenicity [9]. Emerging evidence suggests that miRNAs regulate key signaling pathways that control cancer stem cell self-renewal such as Wnt/β-catenin, Notch and Hedgehog signaling [10]. Thus, therapeutic targeting of cancer stem cell associated miRNAs could represent an attractive strategy to eliminate this highly tumorigenic and therapy-resistant subpopulation of tumor cells. In order to achieve this, it is important to increase our understanding of the mechanisms of action of specific miRNAs in modulating the CSC phenotype. This review will first provide an introduction into the two scientific areas of intense interest at present, cancer stem cells and miRNAs. Subsequently, a concise overview of the role of specific miRNAs in modulating the CSC phenotype will be discussed by concentrating on the following key CSC signaling pathways: Wnt/β-catenin, Notch, Hedgehog, BMI-1 and HMGA2 signalling.
Cancer stem cells
Tumor cells are extremely heterogeneous with regard to their tumorigenic capacity as illustrated by the failure of the vast majority of primary tumor cells to propagate tumors when injected into immunocompromised mice [11]. It is estimated that merely 0.05-1% of tumor cells will propagate secondary tumors in this manner and therefore represent the CSC population [6]. The heterogeneity that exists between individual tumor cells arises from a combination of genetic alterations, microenvironmental influences and alterations in the physical properties of the cells [12-14]. Many questions regarding the source and consequences of tumor heterogeneity remain unanswered such as to what extent is metastasis or therapy resistance a consequence of acquired genetic alterations as opposed to being dependent on the varying physical properties of the cells. For example, it has recently been suggested that varying diffusivity of cellular components could account for disparate responses to therapy [15]. CSCs represent an important subpopulation of cancer cells in many cancer types and are characterised by unlimited replicative potential and give rise to the bulk of the tumor mass by continuous self-renewal and differentiation. CSCs have also been implicated in accelerating metastasis and facilitating resistance to chemo- and radiotherapy [5]. It has been demonstrated that human breast cancer cells displaying a distinct cancer stem cell molecular signature possess enhanced metastatic capacity [16]. Furthermore, cancer stem cells are inherently resistant to standard therapy regimes due to their reduced proliferation rate in comparison to normal cancer cells. The majority of cancer therapeutics target rapidly proliferating cancer cells and therefore quiescent CSCs evade targeting from such therapies [17]. It has also been suggested that cancer stem cell resistance to radiotherapy is mediated by preferential activation of the DNA damage response, and an increase in DNA repair capacity [18].
Cancer stem cells were initially identified in leukemia in which the transition of events from a wild-type immature cell to an immature tumorigenic cell is a well characterized event [6]. It was observed that only a small subset of slowly dividing cells was capable of inducing transplantable acute myeloid leukemia. CSCs have subsequently been identified in a range of solid tumors where the tumor initiating events are less well characterized including, breast, melanoma, colon, ovarian, pancreatic and prostate cancers [19-24]. There is evidence to suggest that cancer stem cells can originate from either normal hematopoietic stem cells or more differentiated progenitor cells, as illustrated in Figure 1. In the case of normal hematopoietic stem cells, the transition to malignant stem cell phenotype could be easily envisioned due to the fact that these multi-potent cells already possess activation of the required self-renewal signaling pathways. Therefore, such cells merely require maintenance of this activated phenotype in contrast to de novo activation in order to propagate the CSC population [25]. Indeed, the leukemia stem cell population capable of propagating acute myeloid leukemia in immunocompromised mice possess a CD34+CD38- phenotype similar to the hematopoietic stem cell phenotype, indicating a normal stem cell origin [26]. However, it has also been demonstrated that cancer stem cells can originate from committed progenitor cells in some subtypes of AML. Indeed, Krivtsov et al., illustrated that leukemia stem cells from leukemia initiated in committed granulocyte macrophage progenitors by introduction of the MLL-AF9 fusion protein were highly tumorigenic when transferred into secondary recipient mice yet maintained an immunophenotype and gene expression pattern analogous to that of the original granulocyte-macrophage progenitor [27]. This indicates that transformational events in differentiated progenitor cells can generate CSCs by activating self-renewal capability without inducing global gene expression reprogramming.
Figure 1: Cancer stem cell development: Cancer stem cells can originate from either normal hematopoietic stem cells or more differentiated progenitor cells. The generation of cancer stem cells from normal hematopoietic stem cells requires a transformational event in conjunction with maintenance of pre-existing self-renewal capacity. Cancer stem cells generated from differentiated progenitor cells require a transformational event in addition to activation of self-renewal signaling pathways.
Several molecular markers have been identified as key regulators of pluripotency, including polycomb group RING finger protein 4 (BMI-1), transcription factor SOX-2 , octomer-binding protein 4 (Oct 4), high mobility group AT-hook protein 2 (HMGA2) [28,29]. These molecular markers play fundamental roles in regulating the activity of normal stem cells and many have also been implicated in the regulation of cancer stem cell activity. In addition, three main signaling pathways have been demonstrated to regulate the unlimited proliferative capacity which defines cancer stem cells: Wnt/β-catenin signaling, Notch signaling and Hedgehog signaling [30]. Therapeutic targeting of these key pathways with the aim of reverting the CSC phenotype represents a plausible mechanism for eradicating the CSC population. One possible strategy is to exploit the multi-target activity of miRNAs in an effort to simultaneously inhibit the expression of multiple components of one or more of these self-renewal pathways.
Recent advances in high-throughput sequencing techniques have unearthed an extensive landscape of small non-coding RNAs in the eukaryotic genome, the most extensively studied of which are miRNAs [31]. MiRNAs are small, single-stranded molecules of approximately 18-25 nucleotides in length that play a fundamental role in virtually all cellular processes [32-34]. MiRNAs form an extensive complex circuitry that mediate post-transcriptional gene silencing and represent a naturally conserved mechanism of regulation that controls approximately 60% of all protein coding genes [35]. MiRNAs bind to complementary sequences within the 3’ untranslated region (UTR) of target mRNAs and mediate mRNA degradation or translational inhibition thereby reducing protein expression [36,37]. The miRNA network is known to co-ordinate normal development and control cell processes such as proliferation, differentiation and apoptosis [38]. Thus, aberrant expression of miRNAs has been linked to many pathological conditions, including the development and progression of cancer [39].
MiRNAs are generally transcribed by RNA polymerase II (Pol II) into primary transcripts termed pri-miRNAs [40]. The primary transcript contains a region in which the sequences are imperfectly complementary forming a structure called a stem-loop or hairpin [41]. In the nucleus, the stem-loop is recognised by the ribonuclease enzyme Drosha which mediates cleavage of the pri-miRNA at the stem of the hairpin structure, releasing a small hairpin termed the pre-miRNA. The pre-miRNA is subsequently transported to the cytoplasm and further cleaved by the ribonuclease Dicer 1 releasing a ~22 nucleotide miRNA duplex [42,43].
The miRNA duplex is then unwound and one strand of the duplex, designated the guide strand, is loaded onto an Argonaute (AGO) protein and incorporated into the RNA-induced silencing complex (RISC). Within the miRISC, the miRNA functions as the guide sequence and dictates which mRNAs to interact with, it is the protein components of the miRISC that execute the silencing of target mRNAs [44]. The miRNA biogenesis pathway is depicted in Figure 2. MiRNAs can mediate mRNA cleavage and degradation at sites of extensive complementarity or mediate direct translational repression and degradation, or a combination of both mechanisms. The ability of a miRNA to target a sequence of limited complementarity allows a single miRNA to regulate the expression of a vast number of mRNA sequences.
Figure 2: MiRNA biogenesis pathway: The biogenesis of miRNAs involves the production of a primary transcript (pri-miRNA) by RNA Pol II which contains a region of imperfect complementarity. The pri-miRNA is cleaved by the ribonuclease enzyme Drosha in the nucleus. The resulting pre-miRNA is exported to the cytoplasm by exportin 5 and further cleaved by Dicer to produce the mature miRNA. The mature miRNA is unwound and one strand is subsequently incorporated into the miRNA-induced silencing complex (miRISC).
MiRNA regulation of cancer stem cell signaling pathways
An extensive collection of experimental data has verified the role of miRNAs in regulating all aspects of tumorigenesis in a wide range of different cancer types [45]. MiRNAs also regulate the fate of embryonic stem cells as demonstrated by the reduced proliferation and defective differentiation associated with Dicer null and DGCR8 null embryonic stem cells [46]. Therefore, it is not surprising that cancer stem cells have exhibited aberrant expression of several miRNAs which dysregulate cancer stem cell self-renewal capacity. An overview of miRNA-mediated regulation of the key CSC signaling pathways is illustrated in Figure 3.
Figure 3: MiRNA biogenesis pathway: The biogenesis of miRNAs involves the production of a primary transcript (pri-miRNA) by RNA Pol II which contains a region of imperfect complementarity. The pri-miRNA is cleaved by the ribonuclease enzyme Drosha in the nucleus. The resulting pre-miRNA is exported to the cytoplasm by exportin 5 and further cleaved by Dicer to produce the mature miRNA. The mature miRNA is unwound and one strand is subsequently incorporated into the miRNA-induced silencing complex (miRISC).
Wnt/β-catenin signaling
The Wnt/β-catenin signaling pathway determines cell fate during embryonic development and also functions as a key regulator of homeostasis in adult self-renewing tissues [47,48]. Wnt proteins are secreted glycoproteins which interact directly with Frizzled-LRP-receptor complexes to activate downstream signaling which results in an accumulation of β-catenin in the cytoplasm. This accumulation of β-catenin is subsequently translocated to the nucleus and activates the expression of a plethora of genes associated with self-renewal [49]. Over-expression of β-catenin has been associated with an increase in the proportion of cancer stem cells. We have previously demonstrated the requirement for Wnt/β-catenin signaling in the development of leukemia stem cells in acute myeloid leukemia [50]. Aberrant activation of the Wnt/β-catenin pathway in more differentiated granulocyte-macrophage progenitor cells, in which Wnt/β-catenin signaling is normally inactive, is not sufficient to drive leukemia, but may provide a permissive environment for malignant transformation [46,50]. Wnt/β-catenin is not an absolute requirement to enable self-renewal of adult hematopoietic stem cells, thus, inhibiting the Wnt/β-catenin pathway represents a therapeutic opportunity for targeting leukemia stem cells.
Wnt/β-catenin also plays a critical role in regulating the activity of cancer stem cells in a wide range of solid cancer types. Disruption of Wnt/β-catenin signaling, which occurs by loss of adenomatous polyposis coli (APC), is a key event in the development of colorectal cancer stem cells [51]. MiR-451 has been identified as a regulator of Wnt/β-catenin signaling in colon cancer. Ectopic over-expression of miR-451 significantly reduces the self-renewal capacity, tumorigenicity and chemoresistance of colonospheres. MiR-451 directly targets macrophage migration inhibitory factor (MIF) gene which regulates the expression of cytochrome c oxidase subunit II (COX-2). COX-2 facilitates β-catenin accumulation which promotes cancer stem cell growth and survival [52]. In hepatocellular carcinoma stem cells, miR-181 regulates Wnt/β-catenin activity by directly targeting the negative Wnt/β-catenin regulator nemo-like kinase (NLK) [53].
Notch signaling
Notch signaling plays a fundamental role in many aspects of embryonic development and the control of tissue homeostasis in adult tissues. Notch is a transmembrane receptor which binds to Delta ligands and is activated by a cascade of proteolytic cleavage events. Newly cleaved Notch is subsequently translocated to the nucleus and activates gene expression by binding to DNA-binding proteins of the CSL family [54]. Aberrant Notch signaling has been demonstrated to promote self-renewal of CSCs. In prostate cancer stem cells, miR-141 and miR-429 directly target and inhibit the expression of the Notch signaling ligand JAGGED1, thereby reducing the rate of cell proliferation [55]. Notably, restoration of miR-34a expression in pancreatic cancer stem cells induces a 90% reduction in the CSC population in addition to significant inhibition of tumor formation in vivo [56]. MiR-34a regulates pancreatic cancer stem cell self-renewal by inhibiting various components of the Notch signaling pathway including, ZEB1 and Snail [57]. MiR-34a has further been demonstrated to target Notch signaling in glioblastoma and medulloblastoma stem cells by directly regulating the Notch-1 and Notch-2 pathway components. MiR-34a expression in glioblastoma cells significantly reduced in vivo xenograft growth and inhibits the tumor propagating ability of medulloblastoma cells [58,59].
Hedgehog signaling
The Hedgehog signaling pathway is a critical regulator of segmental patterning during embryonic development and controls cell proliferation, migration and differentiation [60]. Pathway activation is initiated by binding of one of the three secreted Hedgehog ligands to its receptor Patched. This binding releases Smoothened from its repressed state which modulates the expression of three glioma associated oncogene homologue (Gli) zinc-finger transcription factors. The expression of downstream target genes is modulated by the balance between activated and repressed forms of the Gli proteins [61]. Stimulation of the Hedgehog pathway in hematopoietic stem cells is known to increase self-renewal capacity. The oncogenic miR-17-92 cluster is associated with regulation of Hedgehog signaling. Indeed, enhanced expression of miR-17-92 in medulloblastoma tumors has been demonstrated to activate Hedgehog signaling and accelerate proliferation [62]. A miRNA signature of human medulloblastomas with high levels of Hedgehog signaling has identified miR-125b, miR-326 and miR-324-5p as significantly down-regulated, furthermore, the Smoothened activator and its downstream transcription factor Gli1 were identified as direct target genes [63].
Activation of B cell-specific Molony murine leukemia virus integration site 1 (BMI-1), a stem cell factor and polycomb group family member, has been associated with the enhanced chemoresistance displayed by cancer stem cells [64]. BMI-1 regulates the proliferative capacity of normal, stem and progenitor cells. Up-regulated BMI-1 expression has been identified in a variety of cancer types and positively correlates with clinical stages and poor prognosis. Loss of BMI-1 expression results in a decrease in the neural stem cell population and proliferative capacity [65]. Altering the expression of BMI-1 in breast cancer stem cells modulates the mammosphere-initiating cell population and size [66]. The miR-200 family are known to regulate expression of BMI-1 in addition to other stem cell factors such as SOX, KLF4 and Suz-12. MiR-220b expression has been demonstrated to inhibit the formation and maintenance of mammospheres and to prolong the period of remission in mouse xenograft models when used in conjunction with chemotherapy [67]. MiR-220c has also been verified to target BMI-1 and thereby suppress cancer stem cell growth [68].
Another important stem cell marker and regulator of cancer stem cell self-renewal and survival is HMGA2. HMGA2 plays a role in controlling the proliferation and differentiation of cells during embryonic development [69]. It has been found to be over expressed in several cancer types and associated with disease progression and metastasis [70,71]. HMGA2 is a direct downstream target of the let-7 family of miRNAs. Let-7 was the first miRNA identified in the human genome and extensive research has elucidated its fundamental role in controlling developmental fate and cellular differentiation. Dysregulation of let-7 expression contributes to the development of a malignant phenotype. Yu et al. discovered that let-7 expression was dramatically reduced in the breast cancer stem cell phenotype and that expression increased with differentiation [72]. Forced expression of let-7 in breast cancer stem cells revealed its ability of modulating self-renewal, differentiation and tumorigenic potential by regulating the expression of HMGA2.
The realisation that a cancer stem cell population embodies the true tumorigenic potential of a cancer and is primarily responsible for metastatic dissemination, emergence of therapy resistance and ultimately patient relapse, signifies the requirement for a re-evaluation of our current approach to cancer therapy. In an effort to improve long-term patient survival it is imperative to target the cancer stem cell population. To achieve this, an increase in the understanding of the fundamental signaling pathways driving the self-renewal and survival of these cells is critically important. As illustrated here, it would appear that the cancer stem cell phenotype, regardless of its origin or anatomical predisposition, may be driven by several universal signaling pathways and markers. Thus, the development of a universal cancer stem cell therapy may be a possibility in the near future. MiRNAs have previously been extensively demonstrated to regulate many aspects of cancer development and progression. Accordingly, attention is now focusing on the potential importance of these small non-coding RNAs in the regulation of the vital CSC population. As discussed here, miRNAs play a fundamental role in regulating the cancer stem cell phenotype facilitating the possible use of miRNA therapeutics for the eradication of the CSC population. This review provides a concise overview of currently identified CSC-modulating miRNAs including miR-451 which targets the Wnt/β-catenin pathway, miR-141, miR-429 and miR-34a which regulate various components of the Notch signaling pathway, in addition to the Hedgehog modulating miR-17-92 polycistronic cluster. Currently, intense effort is being employed toward the development of miRNA-mediated therapeutics with technologies such as nanoparticle delivery systems demonstrating significant potential. The development of miRNA-mediated therapeutics remains in its infancy, the true clinical benefit of which remains unknown and is eagerly anticipated. In the interim, it is essential that we continue to expand are understanding of the CSC properties and continue to identify key regulators that serve as drivers of phenotype-switching in distinct cancers.
J.Y.W. is an Australian Research Council Future Fellow (FT120100612). We acknowledge the support of Grants NHMRC APP1045524 from the National Health and Medical Research Council and CINSW 11/CDF/3-38 from the Cancer Institute New South Wales, Australia.
  1. Sporn MB (1996) The war on cancer. Lancet 347: 1377-1381.
  2. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205: 275-292.
  3. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
  4. Shiozawa Y, Nie B, Pienta KJ, Morgan TM, Taichman RS (2013) Cancer stem cells and their role in metastasis. Pharmacol Ther 138: 285-293.
  5. Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785.
  6. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
  7. Chen K, Huang YH, Chen JL (2013) Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 34: 732-740.
  8. Dean M, Fojo T, Bates S (2005) Tumor stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
  9. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006.
  10. Leal JA, Lleonart ME (2013) MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Lett 338: 174-183.
  11. Kordon EC, Smith GH (1998) An entire functional mammary gland may comprise the progeny from a single cell. Development 125: 1921-1930.
  12. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194: 23-28.
  13. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, et al. (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18: 510-523.
  14. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, et al. (2010) Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6: 141-152.
  15. Cherstvy AG, Metzler R (2013) Population splitting, trapping, and non-ergodicity in heterogeneous diffusion processes. Phys Chem Chem Phys 15: 20220-20235.
  16. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, et al., (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273.
  17. Boman BM, Huang E (2008) Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 26: 2828-2838.
  18. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al., (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
  19. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
  20. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, et al., (2008) Identification of cells initiating human melanomas. Nature 451: 345-349.
  21. O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 445: 106-110.
  22. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, et al., (2009) CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27: 2875-2883.
  23. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al., (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
  24. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-1051.
  25. Sell S, Pierce GB (1994) Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 70: 6-22.
  26. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
  27. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, et al. (2006) Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442: 818-822.
  28. Jaenisch R, Young R (2008) Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 132: 567-582.
  29. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, et al. (2002) A stem cell molecular signature. Science 298: 601-604.
  30. Blank U, Karlsson G, Karlsson S (2008) Signaling pathways governing stem-cell fate. Blood 111: 492-503.
  31. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of novel genes coding for small expressed RNAs. Science 294: 853-858.
  32. Wightman B, Ha I, Ruvkun G (1993) Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75: 855-862.
  33. Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, et al. (2005) MicroRNA expression in zebrafish embryonic development. Science 309: 310-311.
  34. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
  35. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
  36. Kim VN, Han J, Siomi MC (2009) Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 10: 126-139.
  37. Eulalio A, Huntzinger E, Izaurralde E (2008) Getting to the root of miRNA-mediated gene silencing. Cell 132: 9-14.
  38. Stadler B, Ivanovska I, Mehta K, Song S, Nelson A, et al. (2013) Characterization of microRNAs involved in embryonic stem cell states. Stem Cells Dev 19: 935-950.
  39. Hwang HW, Mendell JT (2006) MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94: 776-780.
  40. Lee Y, Kim M, Han J, Yeom K, Lee S, et al. (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23:  4051-4060.
  41. Lee Y, Jeon K, Lee JT, Kim S, Kim VN (2002) MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 21: 4663-4670.
  42. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, et al. (2004) The Microprocessor complex mediates the genesis of microRNAs. Nature 432: 235-240.
  43. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, et al. (2001) Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev 15: 2654-2659.
  44. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
  45. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
  46. Wang Y, Medvid R, Melton C, Jaenisch R, Blelloch R (2007) DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat Genet 39: 380-385.
  47. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, et al., (2003) A role for Wnt signaling in self-renewal of haematopoietic stem cells. Nature 423: 409-414.
  48. Malhotra S, Kincade PW (2009) Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. Cell Stem Cell 4: 27-36.
  49. Angers S, Moon RT (2009) Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 10: 468-477.
  50. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, et al., (2010) The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327: 1650-1653.
  51. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, et al. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:  1787-1790.
  52. Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, et al. (2011) MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 29: 1661-1671.
  53. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, et al. (2009) Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50: 472-480.
  54. Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284: 770-776.
  55. Vallejo DM, Caparros E, Dominguez M (2011) Targeting Notch signaling by the conserved miR-8/200 microRNA family in development and cancer cells. EMBO J 30: 756-769.
  56. Ji Q, Hao X, Zhang M, Tang W, Yang M, et al. (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4: e6816.
  57. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S (2011) Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 6: e24099.
  58. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, et al., (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69: 7569-7576.
  59. de Antonellis P, Medaglia C, Cusanelli E, Andolfo I, Liguori L, et al. (2011) MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One 6: e24584.
  60. Varjosalo M, Taipale J (2008) Hedgehog: functions and mechanisms. Genes Dev 22: 2454-2472.
  61. Stecca B, Ruiz IAA (2010) Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol 2: 84-95.
  62. Uziel T, Karginov FV, Xie S, Parker JS, Wang YD, et al. (2009) The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A 106: 2812-2817.
  63. Ferretti E, De Smaele E, Miele E, Laneve P, Po A, et al. (2008) Concerted microRNA control of Hedgehog signaling in cerebellar neuronal progenitor and tumor cells. EMBO J 27: 2616-2627.
  64. Siddique HR, Saleem M (2012) Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 30: 372-378.
  65. Zencak D, Lingbeek M, Kostic C, Tekaya M, Tanger E, et al. (2005) Bmi1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. J Neurosci 25: 5774-5783.
  66. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, et al., (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res  66: 6063-6071.
  67. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601.
  68. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, et al. (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138: 592-603.
  69. Fusco A, Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7: 899-910.
  70. Abe N, Watanabe T, Suzuki Y, Matsumoto N, Masaki T, et al., (2003) An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer 89: 2104-2109.
  71. Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, et al. (2007) HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog 46: 503-511.
  72. Yu F, Yao H, Zhu P, Zhang X, Pan Q, et al. (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123.
Listing : ICMJE   

Creative Commons License Open Access by Symbiosis is licensed under a Creative Commons Attribution 4.0 Unported License